Maternal–Fetal Implications of Mpox Infection: Current Evidence
Mpox is an emerging zoonotic infection caused by the Monkeypox virus, an Orthopoxvirus with increasing global relevance following the 2022 multinational outbreak. Historically endemic to Central and West Africa, the disease has evolved from sporadic zoonotic transmission to sustained human-to-human spread, particularly through close physical and intimate contact. Clinical manifestations typically include fever, lymphadenopathy, and progressive mucocutaneous lesions, although severity varies according to viral clade, immune status, and comorbidities. The 2022 outbreak, predominantly associated with the Clade IIb variant, was characterized by milder disease, localized lesions, and reduced mortality compared with the more virulent Clade I variant. Despite this, severe outcomes remain possible, particularly in vulnerable groups such as children, pregnant individuals, immunocompromised patients, and persons with extensive dermatological disorders. Diagnosis relies primarily on polymerase chain reaction testing from lesion-derived samples, with genomic sequencing serving as a complementary tool for epidemiological surveillance. Management is largely supportive, though antivirals such as tecovirimat may be considered in severe cases or in high-risk populations. Data regarding therapeutic safety in pregnancy are limited; however, tecovirimat appears to have the most favorable profile, whereas cidofovir and brincidofovir remain contraindicated. Prevention strategies include targeted vaccination with the non-replicating Modified Vaccinia Ankara-Bavarian Nordic vaccine, used for both pre- and post-exposure prophylaxis, particularly in individuals at elevated risk. Given the evolving epidemiological profile, the potential for vertical transmission, and the risk of adverse perinatal outcomes, Mpox infection during pregnancy poses unique clinical challenges. This review synthesizes current evidence on virology, clinical presentation, diagnosis, prevention, and management, with an emphasis on obstetric considerations and public health implications.
Authors
- Évelyn Trainá (ORCID: https://orcid.org/0000-0002-6856-8327)
- Camilla Martins dos Santos Maia
- Roberta Granese (ORCID: https://orcid.org/0000-0003-0318-9390)
- Gustavo Yano Callado (ORCID: https://orcid.org/0000-0001-6694-6569)
- B. Rosolen (ORCID: https://orcid.org/0000-0003-3115-9658)
- Edward Araujo Júnior (ORCID: https://orcid.org/0000-0002-6145-2532)
- Giovanna Alves de Britto
- Stefany Silva Pereira (ORCID: https://orcid.org/0009-0000-2733-9301)
- MARCELA FERMOSELLE DE VITA SILVA
- Talita Almeida Durães
- Gabriele Tonni
- Antonio Braga
- Giuliana Augustinelli Sales
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Municipal de São Caetano do Sul (BR)
- Universidade Federal Fluminense (BR)
- Hospital Israelita Albert Einstein (BR)
- University of Vassouras (BR)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3390/jcm15010399
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 0.00